Congratulations, your medical device is a success! But don’t celebrate yet—patent litigation may be next (objectively speaking). Patents are a strategic asset in medtech, where proprietary innovation is key to improving patient outcomes, driving company growth, and securing investment. Since competitors, investors, and opportunistic non-practicing entities (NPE) are aware of the strategic advantages of patents
Medical device manufacturers face mounting pressure to deliver innovative products while reducing costs and improving margins. To meet these challenges, many original equipment manufacturers (OEMs) outsource critical operations such as manufacturing, packaging, and distribution. This shift allows OEMs to streamline resources, eliminate factories and equipment, and focus on innovation, while contract manufacturing organizations (CMOs) step
After several years of volatility and unfavorable market dynamics, the initial public offering (IPO) market for medical technology companies is beginning to reopen meaningfully. Following the most recent IPO boom in 2020 and 2021, higher interest rates and inflation brought new IPO issuances to a near standstill from 2022 to 2024. During that period, many
The healthtech industry is experiencing intense competition as companies race to develop software and artificial intelligence (AI) tools for clinical decision support, medical telemetry, robotic surgery, surgical navigation, medical imaging analysis, drug discovery, clinical trial management, and countless other medical applications. This competitive landscape is driving substantial investment and rapid innovation, with established medtech providers
In the life sciences sector, long-term success is dependent on more than innovation alone. To secure funding, enter strategic alliances, and achieve leadership in competitive markets, companies must protect their innovations by implementing a strategic intellectual property (IP) strategy.
Patents should be the cornerstone of any life science innovator’s business strategy. Across biotechnology, pharmaceuticals, medical
U.S. life sciences companies with ties overseas can be encouraged by a recent federal ruling that denied the request of foreign companies to conduct discovery in the United States in aid of a foreign-seated arbitration. On Jan. 14, 2020, Judge Maryellen Noreika for the District Court of Delaware denied an ex parte application for discovery
Greenberg Traurig’s Tel Aviv office is collaborating with partners BNY Mellon and H.C. Wainwright & Co. LLC to host a morning roundtable focused on capital markets options for the life sciences industry.
The event will take place February 27th, 9:00 at Greenberg Traurig’s Tel Aviv office located in the Azrieli Round Tower (30th Floor).
Topics
Economics in getting a compound approved and commercialized are evolving. Drug companies have reduced budgets that historically funded vast R&D teams. Innovators are chasing tight investment dollars. The two camps are increasingly collaborating.
There is a self-selection factor rewarding start-ups — they can’t attract funding or licensing deals unless they’ve protected their intellectual property, showed
Greenberg Traurig will be sponsoring two major Israel events this coming week.
The first is the OurCrowd Global Investor Summit (January 25-26), set to bring together 3,000 investors and companies from 50 different countries.
Shareholder and Israel Practice Co-Chair, Bob Grossman will be speaking at the opening planery.
Israel Practice Co-Chairan, Tel-Aviv Managing Shareholder, and